European Commission Authorizes Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in 1L CLL June 2, 2026
US FDA Approves INQOVI® in Combination with Venetoclax in AML Patients Ineligible for Intensive Induction Chemo May 21, 2026
First interim unblinding expected in June 2026 following 45 subject enrollment milestone achieved in MIRACLE trial May 21, 2026
Jaypirca (pirtobrutinib) significantly extended PFS when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL April 21, 2026
Wugen Selected for US FDA CMC Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel April 15, 2026
45th subject enrolled in pivotal Ph 2B/3 MIRACLE trial of Annamycin + cytarabine (AnnAraC) for R/R AML March 24, 2026
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% March 17, 2026
FAILED TRIAL: Ph 3 Study of XOSPATA™ (gilteritinib) Did not Meet Primary Endpoint of OS in Patients with Newly Diagnosed FLT3m+ AML March 10, 2026
IND filed with FDA for Ph 2 study of TBS-2025 for the treatment of R/R mutNPM1 AML in combination with a menin inhibitor February 25, 2026
Calquence + venetoclax approved in the US as oral, fixed-duration combination for 1L CLL patients February 25, 2026
QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia February 1, 2026
FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma February 1, 2026
FDA Approves Larger Vial Size for Nelarabine IV Administration for the Treatment of T-ALL and T-LBL February 1, 2026
